2.3.3. Therapeutic Intervention
The following combination (triple therapy) was administered: (1) prolonged-release MPH (OROS formulation), given in the morning at an initial dose of 0.7 mg/kg/day that was adjusted according to response and treatment; (2) aMT, administered at 3 mg/night 30 min before usual bedtime; and (3) a combination of ω-3 PUFAs, consisting of eicosapentaenoic acid (EPA) at 70 mg/day and docosahexaenoic acid (DHA) at 250 mg/day. 